Maynard Um
-
-
-
-
-
-
-
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration
-
-
-
-
-
-
-
Protagonist Therapeutics (PTGX) PT Raised to $104 at Clear Street
-
-
-
-
-
-
-
FDA accepts rusfertide application with priority review for blood disorder
-
-
-
-
-
-
-
Takeda and Protagonist submit drug application for polycythemia vera treatment
-
-
-
-
-
-
-
Protagonist Therapeutics (PTGX) PT Raised to $88 at Truist Securities
-
-
-
-
-
-
-
BMO Capital on Protagonist Therapeutics (PTGX): 'UEG Icotrokinra Full Data Remains Compelling'
-
-
-
-
-
-
-
Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update
-
396,467 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

